Literature DB >> 22297979

A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate.

Varsha Rao1, Jamie C Heard, Helya Ghaffari, Aminah Wali, Laura N Mutton, Charles J Bieberich.   

Abstract

BACKGROUND: Genetically engineered mouse models play important roles in analyses of prostate development and pathobiology. While constitutive genetic gain- and loss-of-function models have contributed significantly to our understanding of molecular events driving these processes, the availability of a tightly regulated inducible expression system could extend the utility of transgenic approaches. Here, we describe the development of a Tet-regulatory system that employs Hoxb13 transcriptional control elements to direct reverse tetracycline transactivator (rtTA) expression in the prostate.
METHODS: Using recombineering technology, the rtTA gene was placed under Hoxb13 cis-regulatory transcriptional control in the context of a 218-kb bacterial artificial chromosome. F(1) offspring carrying the Hoxb13-rtTA transgene were bred to a Tetracycline operator-Histone 2B-Green Fluorescent Protein (TetO-H2BGFP) responder line. Detailed reporter gene expression analyses, including doxycycline (Dox) induction and withdrawal kinetics, were performed in Hoxb13-rtTA|TetO-H2BGFP double transgenic adult mice and embryos.
RESULTS: Dox-dependent GFP expression was observed exclusively in the prostate and distal colon epithelia of double transgenic mice. Reporter gene mRNA was detected in the prostate within 6 hr of Dox exposure, and was extinguished within 24 hr after Dox withdrawal. Furthermore, Dox-induced reporter gene expression persisted after castration.
CONCLUSIONS: The Hoxb13-rtTA transgenic system provides a powerful tool for conditional Tet operator-driven transgene expression in the normal prostate and during disease progression. Used in conjunction with other prostate pathology models, these mice will enable precise, temporally controlled analyses of gene function and can provide opportunities for detailed analyses of molecular events underlying prostate diseases.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297979      PMCID: PMC4133984          DOI: 10.1002/pros.22490

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

1.  Androgen-independent expression of hoxb-13 in the mouse prostate.

Authors:  T Sreenath; A Orosz; K Fujita; C J Bieberich
Journal:  Prostate       Date:  1999-11-01       Impact factor: 4.104

2.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

3.  Defining the epithelial stem cell niche in skin.

Authors:  Tudorita Tumbar; Geraldine Guasch; Valentina Greco; Cedric Blanpain; William E Lowry; Michael Rendl; Elaine Fuchs
Journal:  Science       Date:  2003-12-11       Impact factor: 47.728

4.  Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes.

Authors:  Liwei Huang; Yongbing Pu; David Hepps; David Danielpour; Gail S Prins
Journal:  Endocrinology       Date:  2006-11-30       Impact factor: 4.736

5.  Digital expression profiles of the prostate androgen-response program.

Authors:  Nigel Clegg; Burak Eroglu; Camari Ferguson; Hugh Arnold; Alec Moorman; Peter S Nelson
Journal:  J Steroid Biochem Mol Biol       Date:  2002-01       Impact factor: 4.292

Review 6.  Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.

Authors:  Susan Kasper
Journal:  J Cell Biochem       Date:  2005-02-01       Impact factor: 4.429

7.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

Review 8.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Hoxb13 regulatory elements mediate transgene expression during prostate organogenesis and carcinogenesis.

Authors:  Ryan P McMullin; Laura N Mutton; Charles J Bieberich
Journal:  Dev Dyn       Date:  2009-03       Impact factor: 3.780

10.  Simple and highly efficient BAC recombineering using galK selection.

Authors:  Søren Warming; Nina Costantino; Donald L Court; Nancy A Jenkins; Neal G Copeland
Journal:  Nucleic Acids Res       Date:  2005-02-24       Impact factor: 16.971

View more
  6 in total

1.  Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.

Authors:  Ling Hao; Yatao Shi; Samuel Thomas; Chad M Vezina; Sagar Bajpai; Arya Ashok; Charles J Bieberich; William A Ricke; Lingjun Li
Journal:  Int J Mass Spectrom       Date:  2018-09-22       Impact factor: 1.986

2.  Quantitative proteomic analysis of a genetically induced prostate inflammation mouse model via custom 4-plex DiLeu isobaric labeling.

Authors:  Ling Hao; Samuel Thomas; Tyler Greer; Chad M Vezina; Sagar Bajpai; Arya Ashok; Angelo M De Marzo; Charles J Bieberich; Lingjun Li; William A Ricke
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-17

3.  Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression.

Authors:  Zoila A Lopez-Bujanda; Michael C Haffner; Matthew G Chaimowitz; Nivedita Chowdhury; Nicholas J Venturini; Radhika A Patel; Aleksandar Obradovic; Corey S Hansen; Joanna Jacków; Janielle P Maynard; Karen S Sfanos; Cory Abate-Shen; Charles J Bieberich; Paula J Hurley; Mark J Selby; Alan J Korman; Angela M Christiano; Angelo M De Marzo; Charles G Drake
Journal:  Nat Cancer       Date:  2021-07-19

Review 4.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

Review 5.  Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Authors:  Shazia Irshad; Cory Abate-Shen
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

6.  TGM4: an immunogenic prostate-restricted antigen.

Authors:  Zoila A Lopez-Bujanda; Aleksandar Obradovic; Thomas R Nirschl; Laura Crowley; Rodney Macedo; Alexandros Papachristodoulou; Timothy O'Donnell; Uri Laserson; Jelani C Zarif; Ran Reshef; Tiezheng Yuan; Mithil K Soni; Emmanuel S Antonarakis; Michael C Haffner; H Benjamin Larman; Michael M Shen; Pawel Muranski; Charles G Drake
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.